Nanobiotix Reports 41.7% Response Rate for JNJ-1900 Melanoma Study
Nanobiotix reported a 41.7% response rate for JNJ-1900 in a Phase I study of anti-PD-1-resistant melanoma.
Related stories
Alphabet launches bond sale
Alphabet is issuing bonds, testing appetite for technology-company debt.
M impact | EQUITY | Nov 02, 2026, 02:27 PM UTC
Anthropic Reports About $895.4 Billion in Committed Spend
Anthropic reported aggregate committed spend of about $895.4 billion for purchase commitments and lease agreements as of and subsequent to September 30.
M impact | EQUITY | Nov 02, 2026, 02:27 PM UTC
Shree Pushkar Chemicals Approves 700 Million Rupees for New Plant
Shree Pushkar Chemicals & Fertilisers approved 700 million rupees in capital expenditure for a new chemical plant at Unit-5, Maharashtra.
L impact | EQUITY | Nov 02, 2026, 02:26 PM UTC
Privia Health Group Acquires American Choice Healthcare for $36 Million
Privia Health Group said it acquired American Choice Healthcare for $36 million.
M impact | EQUITY | Nov 02, 2026, 02:26 PM UTC
US Stock Index Futures Rise After Oil Drop and Recent Equity Selloff
US stock index futures rose after an oil drop and a recent equity selloff.
M impact | EQUITY | Nov 02, 2026, 02:26 PM UTC
IKEA Store in Belgium Hit by Fridge Cyberattack
A cyberattack involving a fridge hit an IKEA store in Belgium, Reuters reported.
M impact | EQUITY | Nov 02, 2026, 02:26 PM UTC